PCCПолипептидный комплекс хрящевой ткани
A polypeptide mixture extracted from animal cartilage. The preparation contains the tripeptide Ala–Glu–Asp (AED), which has also been studied separately as synthetic Cartalax.
What the studies found
Review of earlier studies · 2023
Peptide Regulation of Chondrogenic Stem Cell Differentiation
Study of multiple preparations
Describes the cartilage polypeptide complex PCC and its AED component. The authors reported a Russian Phase II osteoarthritis program in 2023. They connect MSC and fibroblast findings to a cartilage-repair hypothesis.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model Review of stem-cell differentiation and cartilage research
Important limitations
- The reported trial concerns PCC, not a trial of isolated Cartalax. Trial identifier, protocol, enrollment and published human outcomes have not been recovered. Phase II is an attributed 2023 statement, not verified current status.
Int J Mol Sci 24(9):8415. PMID 37176122 · Publication record
Laboratory analysis · 2020
Identification of short peptides in the composition of polypeptide complexes isolated from animal organs
Study of multiple preparations
- EDG and AEDL in the bronchial mucosa complex
- EDG 0.028% and AEDL 0.060% of the analyzed extract
Reports KED in vessel complex, AED in cartilage, EDG and AEDL in bronchial mucosa, EDR in brain and KEDW in pancreas. This strengthens sequence-level links in the research program.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
Study notes · methods, sources and limitations
Participants or model Animal-organ polypeptide complexes analyzed by UHPLC–MS
Design UHPLC–tandem mass spectrometry of six lyophilized animal-tissue complexes, using reference standards for seven target sequences.
Important limitations
- Molecular detection does not prove identical pharmacology or clinical equivalence. The paper’s discussion of clinical work is not an independent clinical trial.
- These measurements describe the analyzed preparations. The paper does not characterize all constituents or identify the clinical trial batch.
Uspekhi Sovremennoi Biologii 140(2):140–148 · Publication record
About PCC
Names in this research collection
Cartilage polypeptide complex · PPC · Cartilage extract
Research background
An animal-cartilage-derived polypeptide complex described in the Russian cartilage research program. It is a mixture containing AED, not a synonym for synthetic Cartalax.
- Compound class
- Tissue-derived polypeptide complex
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Trial program reported in review; primary trial unrecovered
Study methods
Original reports separated from narrative reviews and patents
Independent replication
Independent replication not established by this collection
Source access
Linked abstracts, analytical papers, reviews and patents; individual scope shown below
Safety evidence
Incomplete assessment; findings do not establish safety for personal use
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Experiment described in a patent · 2008
PCC: corrected cartilage-complex publication — RU2302872C9
Pain reduction is reported, but the percentage and patient count do not yield a clear responder denominator.
Pain improvement · Reported in 67.4% of cases · The text does not explain how this percentage maps to the 15 treated participants · After a 20-day course
Study notes and original source
PCC: corrected cartilage-complex publication — RU2302872C9
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Владимир Хацкелевич Хавинсон (RU), Владимир Хацкелевич Хавинсон, Владимир Викторович Малинин (RU), Владимир Викторович Малинин, Галина Анатольевна Рыжак (RU), Галина Анатольевна Рыжак · RU2302872C9 · patent family 38431016
Pain reduction is reported, but the percentage and patient count do not yield a clear responder denominator.
Results and tables
Reported patent results
Findings described in words
Pain reduction is reported, but the percentage and patient count do not yield a clear responder denominator.
Corrected PCC publication: 33 lumbar-osteochondrosis patients, 15 extract versus 18 saline, alongside complex care.
Population or model Corrected PCC publication: 33 lumbar-osteochondrosis patients, 15 extract versus 18 saline, alongside complex care.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pain improvement | Reported in 67.4% of cases | The text does not explain how this percentage maps to the 15 treated participants · After a 20-day course |
| Cartilage-culture findings | Growth-stimulation experiments described in rat cartilage fragments | Laboratory tissue findings are separate from the patient pain report |
The pain outcome is insufficiently specified and co-treatment complicates attribution. Use the corrected C9 claim text; this cartilage complex is not defined AED Cartalax.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Corrected PCC publication: 33 lumbar-osteochondrosis patients, 15 extract versus 18 saline, alongside complex care.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- Use the corrected claim text, not the erroneous C1 text, when tracing the cartilage preparation. A tissue complex is not a single defined peptide.
- The pain outcome is insufficiently specified and co-treatment complicates attribution. Use the corrected C9 claim text; this cartilage complex is not defined AED Cartalax.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Review of earlier studies · 2023
Peptide Regulation of Chondrogenic Stem Cell Differentiation
Describes the cartilage polypeptide complex PCC and its AED component. The authors reported a Russian Phase II osteoarthritis program in 2023. They connect MSC and fibroblast findings to a cartilage-repair hypothesis.
Study notes and original source
Peptide Regulation of Chondrogenic Stem Cell Differentiation
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Linkova N, Khavinson V, Diatlova A, Myakisheva S, Ryzhak G · Int J Mol Sci 24(9):8415. PMID 37176122
Describes the cartilage polypeptide complex PCC and its AED component. The authors reported a Russian Phase II osteoarthritis program in 2023. They connect MSC and fibroblast findings to a cartilage-repair hypothesis.
- Population / setting
- Review of stem-cell differentiation and cartilage research
- Source reviewed
- Full-text XML checked, including PCC/AED discussion and references 7, 9, 68–70. Trial documents were not supplied by this review.
Study limitations
- The reported trial concerns PCC, not a trial of isolated Cartalax.
- Trial identifier, protocol, enrollment and published human outcomes have not been recovered. Phase II is an attributed 2023 statement, not verified current status.
Reviewed 2026-09-29.
Laboratory analysis · 2020
Identification of short peptides in the composition of polypeptide complexes isolated from animal organs
Reports KED in vessel complex, AED in cartilage, EDG and AEDL in bronchial mucosa, EDR in brain and KEDW in pancreas. This strengthens sequence-level links in the research program.
Study notes and original source
Identification of short peptides in the composition of polypeptide complexes isolated from animal organs
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
I. K. Zhurkovich, N. G. Kovrov, G. A. Ryzhak, E. S. Mironova, V. Kh. Khavinson · Uspekhi Sovremennoi Biologii 140(2):140–148
Reports KED in vessel complex, AED in cartilage, EDG and AEDL in bronchial mucosa, EDR in brain and KEDW in pancreas. This strengthens sequence-level links in the research program.
Results and tables
Reported findings and study design
UHPLC–tandem mass spectrometry of six lyophilized animal-tissue complexes, using reference standards for seven target sequences.
Population or model Animal-organ polypeptide complexes analyzed by UHPLC–MS
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| EDG and AEDL in the bronchial mucosa complex | EDG 0.028% and AEDL 0.060% of the analyzed extract |
Identified short peptides by extract
| Extract | Sequence | Reported proportion |
|---|---|---|
| Bronchial mucosa | EDG | 0.028% |
| Bronchial mucosa | AEDL | 0.060% |
| Vessels | KED | 0.020% |
| Cartilage | AED | 0.020% |
| Brain | EDR | 0.024% |
| Pancreas | KEDW | 0.035% |
These measurements describe the analyzed preparations. The paper does not characterize all constituents or identify the clinical trial batch.
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- Animal-organ polypeptide complexes analyzed by UHPLC–MS
- Source reviewed
- Original analytical paper, test method, Table 3 and chromatograms in Figures 1–6.
Study limitations
- Molecular detection does not prove identical pharmacology or clinical equivalence.
- The paper’s discussion of clinical work is not an independent clinical trial.
Reviewed 2026-11-15.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗